[Skip to Content]
[Skip to Content Landing]
October 1972

Comparative Trial of HPV-77, DE-5 and RA 27/3 Live-Attenuated Rubella Vaccines

Author Affiliations

Buffalo, NY
From the Vaccine Evaluation Unit, Department of Social and Preventive Medicine, State University of New York at Buffalo, and the Center for Disease Control, Public Health Service, Atlanta. Drs. Wallace and Isacson are currently at the Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Iowa City.

Am J Dis Child. 1972;124(4):536-538. doi:10.1001/archpedi.1972.02110160074007

An experimental live, attenuated rubella vaccine, RA 27/3, was compared with HPV-77, DE-5 rubella vaccine (Meruvax) in children in an open school setting. Seroconversion of RA 27/3 vaccines administered by either intranasal or subcutaneous route and HPV-77, DE-5 given subcutaneously was 95% or greater as measured by hemagglutination-inhibition antibody (HI). However, RA 27/3 vaccine produced significantly greater seroconversion rates and titer levels by complement-fixation antibody (CF) testing, when compared with HPV-77, DE-5 vaccine. No serious reactions were noted, and there were no joint reactions in any study group during the 28-day postimmunization follow-up period or upon recontacting vaccine recipients one year later. Intranasal immunization was well tolerated.